<ѻýҕl>ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancerѻýҕl> Adjuvant alectinib reduces disease-free survival hazard by 76% Oct 24, 2023
<ѻýҕl>Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancersѻýҕl> Still some unanswered questions about benefit over other drug regimens, expert says Oct 24, 2023
<ѻýҕl>Randomized Trial Backs HIF-2a Inhibition in Advanced RCCѻýҕl> After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus Oct 24, 2023
<ѻýҕl>More Data Support Adding Immunotherapy to Chemo in Advanced Endometrial Cancerѻýҕl> PFS doubled and OS improved, driven by mismatch repair-deficient disease Oct 23, 2023
<ѻýҕl>Antibody-Drug Conjugate Boosts Survival in Recurrent/Metastatic Cervical Cancerѻýҕl> Tisotumab vedotin reduced risk of death by 30% compared with chemotherapy Oct 23, 2023
<ѻýҕl>Targeted Combination Wins in KRAS-Positive Metastatic Colorectal Cancerѻýҕl> Standard dose of sotorasib plus panitumumab reduced risk of progression by 51% vs standard care Oct 23, 2023
<ѻýҕl>New First-Line Standard for Lung Cancers With EGFR Exon 20 Insertionsѻýҕl> Adding amivantamab to chemotherapy improved PFS, induced more rapid and durable responses Oct 23, 2023
<ѻýҕl>'Practice-Changing' Data in Locally Advanced Cervical Cancerѻýҕl> Strategies involving immunotherapy, induction chemo move the needle for first time in decades Oct 23, 2023
<ѻýҕl>RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLCѻýҕl> Two randomized studies demonstrate significantly improved PFS against standard regimens Oct 22, 2023
<ѻýҕl>Landmark Trial Produces New First-Line Standard for Advanced Bladder Cancerѻýҕl> Enfortumab vedotin-pembrolizumab doubles OS, PFS versus chemotherapy Oct 22, 2023
<ѻýҕl>Bi-Specific T-Cell Engager Active in Small-Cell Lung Cancer in Third Line and Beyondѻýҕl> Tarlatamab achieves 40% overall response rate at the dose selected for continued evaluation Oct 22, 2023
<ѻýҕl>Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancerѻýҕl> Durvalumab plus olaparib, or alone, paired with chemo boosts PFS in DUO-E trial Oct 21, 2023
<ѻýҕl>Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Yearsѻýҕl> And early ctDNA reductions correlated with survival Oct 21, 2023
<ѻýҕl>Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancerѻýҕl> But label update planned after potential harm observed in PD-L1-negative subgroup Oct 20, 2023
<ѻýҕl>Hand Cooling, Compression Both Effective for Nerve Pain in Breast Cancerѻýҕl> But access, cost, and tolerability may favor the latter option, said researcher Sep 14, 2022
<ѻýҕl>Potential Practice-Changer for Refractory Metastatic Colon Cancerѻýҕl> Significant survival gain with fruquintinib in patients with heavily pretreated disease Sep 14, 2022
<ѻýҕl>Non-Chemo Regimen Led to High Response Rates in Cisplatin-Ineligible Bladder Cancerѻýҕl> "Encouraging activity" with enfortumab vedotin-pembrolizumab in patients with high unmet need Sep 14, 2022
<ѻýҕl>Long-Term ADT With Radiation Helps Prevent Post-Prostatectomy Metastasesѻýҕl> However, no benefit seen with short-term hormone therapy versus radiotherapy alone Sep 13, 2022
<ѻýҕl>Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanomaѻýҕl> Large increase in event-free survival with neoadjuvant plus adjuvant versus only adjuvant therapy Sep 13, 2022
<ѻýҕl>KRAS Inhibitor Tops Docetaxel for Previously Treated NSCLCѻýҕl> "New second-line standard" in KRAS G12C-mutant disease, says study investigator Sep 13, 2022
<ѻýҕl>Triplet in First-Line Kidney Cancer Thwarts Disease Progressionѻýҕl> Randomized study shows "clinically meaningful" PFS improvement over dual immunotherapy alone Sep 13, 2022
<ѻýҕl>Survival Bump in Unfit NSCLC With First-Line Immunotherapyѻýҕl> Atezolizumab doubles OS at 2 years versus chemotherapy in those ineligible for platinum doublets Sep 12, 2022
<ѻýҕl>Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinomaѻýҕl> Pathologic complete responses seen in 63% of patients in phase II data Sep 12, 2022
<ѻýҕl>Three Adjuvant Immunotherapy Trials Flop in Renal Cell Carcinomaѻýҕl> Studies appear to contradict benefit previously shown with pembrolizumab in this setting Sep 12, 2022
<ѻýҕl>Combination Therapy Shows Promise for NSCLC That Progresses on Osimertinibѻýҕl> About half of patients responded to tepotinib plus osimertinib, but efficacy ceiling persists Sep 12, 2022
<ѻýҕl>'Striking' Colon Cancer Data Spur Mid-Presentation Ovation at ESMOѻýҕl> Preoperative immunotherapy combo in dMMR disease yields major pathologic response in 95% Sep 12, 2022
<ѻýҕl>Tumor Infiltrating Lymphocytes Reemerge as Potential Melanoma Optionѻýҕl> More than 50% increase in 6-month PFS versus ipilimumab after progression on first-line anti-PD-1 Sep 12, 2022
<ѻýҕl>Add-On Pembrolizumab Misses in Locally Advanced Head and Neck Cancerѻýҕl> Post hoc data point to possible benefit in patients with higher PD-L1 levels Sep 11, 2022
<ѻýҕl>Locking Down a Link Between Pollution and EGFR-Mutated Lung NSCLCѻýҕl> Study also shed lights on what may lead to lung cancer in never smokers Sep 11, 2022
<ѻýҕl>'Potential New Standard' for Progressing Desmoid Tumorsѻýҕl> Risk of disease progression or death reduced by 71% with oral gamma secretase inhibitor Sep 10, 2022
<ѻýҕl>Targeted Combo Flops as First-Line Treatment in Advanced Breast Cancerѻýҕl> No clinical benefit boost with anti-CD73 oleclumab added to durvalumab and chemo Sep 10, 2022
<ѻýҕl>Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trialsѻýҕl> Results from SOLO-1 and PAOLA-1 show "clinically meaningful" long-term results with olaparib Sep 09, 2022
<ѻýҕl>Worse OS With Rucaparib First in Trial of Recurrent, BRCA+ Ovarian Cancerѻýҕl> A closer look at why PARP inhibitor's third-line indication was withdrawn Sep 09, 2022
<ѻýҕl>Antibody-Drug Conjugate Prolongs Survival in Metastatic Breast Cancerѻýҕl> Positive outcome with sacituzumab govitecan leads to questions about ADC sequencing Sep 09, 2022
<ѻýҕl>Checkpoint Inhibitors Whiff in Head and Neck Cancer Trialsѻýҕl> Avelumab, nivolumab-ipilimumab, pembrolizumab miss endpoints in separate studies Sep 23, 2021
<ѻýҕl>Survey Says: Support Is Lacking for Cancer's Lingering Effectsѻýҕl> Survivors report dissatisfaction with long-term support Sep 22, 2021
<ѻýҕl>Angiogenesis Inhibitor Slows Extrapancreatic Neuroendocrine Tumorsѻýҕl> Almost 7-month increase in median PFS with addition of axitinib to endocrine therapy Sep 21, 2021
<ѻýҕl>Transarterial Radioembolization Slows Progression of CRC With Liver Metsѻýҕl> Small increase in median PFS when combined with second-line chemotherapy Sep 21, 2021
<ѻýҕl>Androgen-Targeting Combos Show Promise in Prostate Cancerѻýҕl> Trials extend survival in hormone-sensitive disease Sep 21, 2021
<ѻýҕl>Bifunctional Protein Shows Promise in HPV-Related Cancersѻýҕl> Objective responses in 28% of pretreated patients, durable in most cases Sep 20, 2021